Litt’s Drug profile for Oxymetazoline


BreastfeedingPediatric
  • FDA Approval Date: 01/18/2017
  • Clinically important, potentially hazardous interactions with:
    None known
  • Pregnancy: No available data to inform drug-associated risk

For topical use only. See separate entry for tetracaine & oxymetazoline as intranasal formulation.

Oxymetazoline is also available as an ophthalmic solution and a nasal decongestant in over-the-counter products.

Please login to view the rest of this drug profile.

Page last updated 04/09/2026

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric